These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1653 related articles for article (PubMed ID: 26729007)

  • 1. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
    Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
    J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
    Zeidler J; Mahlich J; Greiner W; Heres S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
    Citrome L; Kamat SA; Sapin C; Baker RA; Eramo A; Ortendahl J; Gutierrez B; Hansen K; Bentley TG
    J Med Econ; 2014 Aug; 17(8):567-76. PubMed ID: 24758296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
    Augusto M; Greene M; Touya M; Sweeney SM; Waters H
    J Comp Eff Res; 2018 Jul; 7(7):637-650. PubMed ID: 29694244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
    Einarson TR; Pudas H; Goswami P; van Impe K; Bereza BG
    J Med Econ; 2016; 19(2):111-20. PubMed ID: 26414966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.
    Dilla T; Möller J; O'Donohoe P; Álvarez M; Sacristán JA; Happich M; Tockhorn A
    BMC Psychiatry; 2014 Dec; 14():298. PubMed ID: 25438678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
    Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
    J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
    Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
    Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France].
    Gozlan G; Lecardeur L; Monfort AS; Doz M; Ortiz I; Larroumets P; Lafuma A
    Encephale; 2018 Dec; 44(6):496-503. PubMed ID: 30482480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
    Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
    Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
    Laux G; Heeg B; van Hout BA; Mehnert A
    Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.
    De Graeve D; Smet A; Mehnert A; Caleo S; Miadi-Fargier H; Mosqueda GJ; Lecompte D; Peuskens J
    Pharmacoeconomics; 2005; 23 Suppl 1():35-47. PubMed ID: 16416760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
    Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
    Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
    Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
    J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 83.